BIOMARKERS & IMMUNO US:
In-Person

6th Annual Biomarkers & Precision Medicine USA Congress | **4th Annual Advances in Immuno-Oncology USA Congress**

03 - 04 October 2022 | San Diego, USA

300+
LEADING PHARMA, BIOTECH AND ACADEMIC DELEGATES

60+
PRESENTATIONS, CASE STUDIES AND DISCUSSIONS

9
INTERACTIVE TRACKS ON THE LATEST INNOVATIONS

Conference Brochure

KEY SPEAKERS INCLUDE

Ken Chang
Daiichi Sankyo

Mehran Moghaddam
OROX Biosciences, Inc.

Ewa Carrier
Fibrogen

Jadwiga Bienkowska
Pfizer

Jeffrey Wallin
Gilead Sciences Inc

Kelly Shanahan
Living with Metastatic Breast Cancer

More Information: Biomarkers US | Immuno US
Join the Conversation: #BiomarkersSeries22 | #IMMUNOSeries22

OXFORD GLOBAL CONFERENCES

BROCHURE CONTENTS

WELCOME

With the co-located Biomarkers and Immuno US Conference coming up soon, I am very excited to reveal what we have in store for you during our interactive & engaging conference.

This conference will unite senior-level experts to provide a focussed forum for thought-provoking discussion and to gain insights from the key figures in the community. This year's comprehensive programme will enable you to gain a forward-looking perspective on the latest technologies and strategies impacting biomarker research, alongside in-depth considerations of advancing Immuno-Oncology drug development.

This year's Biomarkers & Precision Medicine programme will enable you to benefit from updates on utilising biomarkers for translational science, diagnostics and clinical development. Further sessions provide insights into topical technology innovation in this space, from the latest imaging tools and AI strategies through to genomic technologies for precision medicine.

Our Immuno-Oncology programme will provide case studies on a variety of key therapeutic modalities, including cell therapies, combination strategies and novel antibodies. Alongside this, there will be discussion on advancing preclinical models and developing effective biomarker strategies. As a new area of focus, the agenda will include sessions on targeting the tumour microenvironment through spatial biology, imaging and pathology

This packed conference will provide this cutting-edge content through presentations, panel discussions and speaker Q&As.

We are hugely thankful to our speakers, who have given their time to deliver interesting, thought-provoking presentations, and to our sponsoring companies, who have worked closely with us to provide you with unique opportunities to access the latest information on solutions and services that can directly impact and improve your research

and results. Without their support this event would not be possible, so please do take some time to visit them on-site, but also their featured sponsor pages on the accompanying event app and engage with the content and resources that they have made available.

Networking & knowledge-sharing is at the heart of what we do. Apart from the innovative programme, your event experience will be linked to the Swapcard event app, where you can engage in a variety of event features including AI-based suggestions to make connections, creating a personalised conference agenda, chat through text or video and the ability to access peer to peer networking. The event platform will allow you to exchange contact details, files and links freely to build a wealth of information for your use, post-event. To get the most out of the conference, the accompanying platform will be open 7-days before the start of the conference.

To maximise your access to available resources at the event we have created the Digital Gallery, on the digital platform where you can find a host of product information or informative content most relevant to you and your research interests.

If you have any questions, please contact a member of the team on-site and we will be available to assist and ensure you get the best experience you can from the event.

We look forward to welcoming you to the conference. See you then!

Hayley Watson,
Senior Director, Commercial Strategy

On-site Health & Safety

At Oxford Global, the safety and well-being of our clients is our top priority, and we are committed to ensuring that our congresses remain safe and successful.

For more information, please see www.oxfordglobal.co.uk/biomarkers-series-us/plan-your-visit/

300+ VPs, Directors & Senior Managers will be attending, coming from leading healthcare, biotech, pharma and research institutions in the following fields and more:

- Biomarker Discovery
- Translational Science
- Clinical Development
- Assay Development
- Genomic Markers
- Diagnostics

- Personalised Medicine
- Biomarker Technologies
- Immuno-Oncology
- Cancer Immunology
- Oncology Biomarkers
- Cell & Gene Therapy

- Translational Immunology
- Preclinical & Clinical Oncology
- Combination Therapy
- Antibody Development
- Biomarker Verification

Projected Attendee Profile

- 60% Industry
- 33% Vendor Companies
- 7% Academic

SECTOR

- 44% Director or Professor
- 39% Senior Manager or Senior Scientist
- 17% Commercial

FUNCTION

- 85% USA
- 11% Europe
- 15% Rest of The World

GEOGRAPHY

These companies and many more:

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Assay Kits & Platforms
- Biomarker Verification
- Companion Diagnostics
- Protein Biomarkers
- Clinical Research & Trial Development

- Genomic Technologies
- Imaging Tools
- Liquid Biopsy
- Plexing Platforms
- Immunoassays

- Data Management
- Biomarker Discovery & Development
- Digitalisation & Digital Technologies
- Molecular & Digital Pathology

Gold Sponsors

BIOCARTIS

GemPharmatech™

nexelis
a Q² Solutions Company

Personalis®

somalogic

U Ultivue

Silver Sponsors

BioLizard

canopy
BIOSCIENCES A BRUKER COMPANY

Cerba Research

charles river

DermTech STRATUM

IONPATH

mlm medical labs®

NEO GENOMICS

REACTION BIOLOGY

SAPIENT

sengenics

STANDARD BIOTOOLS™

Bronze Sponsors

ARIMA GENOMICS

Volition

Veranome Biosystems

CDD.VAULT®
Complexity Simplified

BIOGNOSYS
NEXT GENERATION PROTEOMICS

Network & Programme Sponsors

ABL inc.
ADVANCED BIOSCIENCE LABORATORIES

AstraZeneca

BIOIVT
ELEVATING SCIENCE®

CHAMPIONS ONCOLOGY

DEXTER

Dimensions

fios GENOMICS

HAWK Biosystems

IMMUNITRACK

indivumed

inovotion
WHICH MOLECULE WILL STAND OUT

mirxes
TO KNOW. TO ACT.

MilliporeSigma

molecular you PERSONALIZED HEALTH

NOVAI

proteiQ

proteome sciences

RULES BASED MEDICINE
a Q² Solutions Company

Sanyou Bio
Antibody Drug R&D
Ask Sanyou Bio

Ziath

To view the full list of Sponsors and their profiles please visit
www.oxfordglobal.co.uk/biomarkers-series-us/sponsorship/

Biomarkers & Immuno US: In-Person features **2 days** of in-person cutting-edge presentations and knowledge-sharing, including **over 60** industry insights, sponsored presentations, think tank roundtable discussions and followed by digital access to on-demand content delivered through our **online event platform**.

DAY ONE - 03 OCTOBER 2022

Track 1.1: Biomarkers in Drug Discovery & Translational Science

- Case studies in biomarker validation in: Neuroscience, Rare diseases, Immunology, Oncology & Cardiovascular disorders
- Qualification of biomarkers for translational studies
- Efficacy and PK/PD biomarkers in drug development

Track 1.2: Biomarkers for Precision Medicine & Diagnostic Development

- Diagnostic Development: Companion, Tissue & PoC
- Enabling personalised medicine & demonstrating clinical utility
- Case studies in targeted therapies for oncology
- Biospecimens for qualification and validation for precision medicine

Track 2: Biomarkers for Clinical Development

- Transforming clinical development through biomarker driven clinical trial design
- Use of molecular biomarkers in clinical trials
- Overcoming challenges of clinical validation & translation
- Case studies in the optimization of trial design

Track 3: Discovery & Development: Cell Therapies & Antibody Approaches

- Traditional Cell Therapies - T-Cells and NK Cells
- Non-Conventional Cell Therapies - Macrophages and TCRs
- Latest antibody-based approaches, including bispecifics

Track 4: Biomarkers & Precision Medicine in Immuno-Oncology

- Novel biomarkers in the Immuno-Oncology research
- Improving patient responses through biomarker development
- Diagnostic tools within I-O, including liquid biopsies for precise treatments

DAY TWO - 04 OCTOBER 2022

Track 1: Biomarker Analysis & Emerging Technologies

- Big data analytics and sampling techniques
- Imaging technologies, CNS imaging techniques & digital pathology
- Multiplexing technologies, Flow cytometry & Mass spectrometry
- Digital Pathology Tools & Technologies

Track 2: Genomic Markers For Precision Medicine & Clinical Research

- Case studies in CTCs
- Importance of liquid biopsies for precision medicine in oncology
- Using NGS and Single Cell Genomic Technologies in Clinical Development
- Understanding genetic variants as the basis of disease

Track 3: Discovery & Development: Intra-tumoral Immunotherapies & Combination Strategies

- Oncolytic and non-oncology viruses & agonists
- Delivering intra-tumoral immunotherapies for solid tumours
- Rational of different combinations, including combination of IO agents as well as radiotherapy & chemotherapy

Track 4: Translational & Preclinical Development

- Assay development, including pharmacodynamic assays
- Translating animal models into human and clinically-relevant models for screening therapies
- Safety & toxicity considerations
- Application of spatial biology tools in the tumor microenvironment

NICOLE BJORKLUND
Director, Translational Research & Development, Cohen Veterans Bioscience

SIMONE FILOSTO
Director, Cell Biology, Translational Medicine, Kite Pharma

EWA CARRIER
Vice President, Clinical Development, Fibrogen

ALEKHYA POCHIRAJU
Product Development, Global Operations Manager, Genentech

MICHELLE GRAHAM
Principal Research Scientist, AbbVie

CHRISTIE FANTON
Vice President, Translational Medicine, Nektar Therapeutics

GRAHAM JONES
Head of Research and Innovation, Novartis

E.J. DETTMAN
Principal Scientist, Clinical Research, Merck

MIKE DAMORE
Director, Translational Oncology Lead, Pfizer

SIMI AHMED
Senior Vice President, Strategic Partnerships, NYSCF

YOUG THAKER
Principal Scientist, Sorrento Therapeutics

JADWIGA BIENKOWSKA
Senior Director, Computational Biology ORD, Pfizer

BONNIE HAMMER
Senior Vice President, Research & Development, Invenra, Inc.

KOUSTUBH RANADE
Head of Translational Medicine, Immunocore

AUDE-HELENE CAPIETTO
Senior Principal Scientific Researcher, Cancer Immunology Department, Genentech

ANDREW ALLEN
Co-Founder, President and Chief Executive Officer, Gritstone bio

BYUNG HA LEE
Senior Vice President & Chief Scientific Officer, NeoImmuneTech

NADIA HASSOUNAH
Principal Scientist, Translational Immuno-Oncology, Novartis

MICHAEL GROANING
Global Medical Affairs Lead Genitourinary, Amgen

CONRAD MESSAM
Senior Director, Merck

KATIE NEWHALL
Vice President Translational Clinical Development, Cellectis

TOBIN CAMMETT
Director - Biomarker Development, Alexion Phamaceuticals, Inc

ANDERS DAMHOLT
Head of Clinical Development - Human Health, Chr. Hansen

DAVE HOON
Professor, Director, St. John's Cancer Institute

VILMA DECMAN
Senior Director, Head of the Cellular Biomarkers, GSK

KELLY SHANAHAN
Advocate, Living With Metastatic Breast Cancer

JEFFREY WALLIN
Executive Director, Biomarker Sciences, Gilead Sciences Inc

HONG LIN
Head of Clinical Immunology/Flow Cytometry, Stony Brook University School of Medicine

KEN CHANG
Director, Clinical Biomarkers, Daiichi Sankyo

MICHAEL ROEHRL
Professor of Pathology, Lab Medicine, Cell & Developmental Biology, Memorial Sloan Kettering Cancer Center

ANAND GIDDABASAPPA
Head of Global Science and Technology, Comparative Medicine, Pfizer

SEAN XIE
Director, Drug Safety Research & Development, Pfizer

KATHERINE CALL
Former Senior Director, Biomarkers, Sanofi

CHIH-LIANG CHIN
Executive Director, Biomarker & Target Sciences, Merck & Co., Inc.

JOHN LU
Chief Executive Officer, Hebecell Corporation

RUSSELL LAMONTAGNE
President and Chief Executive Officer, LaMontagne Gallery

JOHN ROSSI
Vice President, Head of Translational Medicine, Syncopation Life Sciences

PHILIP ARLEN
President and Chief Executive Officer, Precision Biologics, Inc

TAUSEEF BUTT
President and Chief Executive Officer, LifeSensors Inc

PRAVIN KAUMAYA
Professor of Medicine and Director Vaccine Development, The Ohio State University

KENNETH RAMOS
Executive Director, Texas A&M Institute of Biosciences and Technology

SETH CROSBY
Director, Research Collaborations, Washington University

GIULIO PACIOTTI
Chief Science Officer, Cytimmune Sciences, Inc.

LILING WARREN
Senior Director, Head of Translational Statistics, Teva Pharmaceuticals

MEHRAN MOGHADDAM
Chief Executive Officer, OROX BioSciences, Inc.

DIANA PRICE
Executive Director, Biosciences, Neuropore Therapeutics, Inc.

SRIPAD RAM
Digital Pathology and Image Analysis Group Lead, Pfizer

SARA FERNANDO-MARTINEZ
Principal Scientist; Head of Clinical Sciences, NeoImmuneTech

AMANDA KLEIN
Executive Director, Transplant Therapeutics Consortium, Critical Path Institute

For more information on our speakers,
please read the biographies available on our **event app**

DAY ONE: 03 OCTOBER 2022

08:20 — **Oxford Global Welcome Address & Chairperson's Opening Address**

08:30

Opening Keynote Address: Discovery Of Biomarkers For Immuno-Oncology Therapies
- Identification of clinical biomarkers for Phase 1 from analysis of single cell sequencing in preclinical models and patient samples
- Clinical Biomarker development of response from phase 3 clinical trials with analysis multi omics data with applications of machine learning
- Discovery of mechanism of resistance to IO therapies to inform new targets and combinations

JADWIGA BIENKOWSKA, Senior Director, Computational Biology ORD,
Pfizer

ROOM 1: BIOMARKERS IN DRUG DISCOVERY & TRANSLATIONAL SCIENCE	ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT	ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: CELL THERAPIES & ANTIBODY THERAPIES	ROOM 4: BIOMARKERS & PRECISION MEDICINE IN IMMUNO-ONCOLOGY
Track Chair: NICOLE BJORKLUND, Director, Translational Research & Development, **Cohen Veterans Bioscience**	**Track Chair:** KATIE NEWHALL, Vice President of Translational Clinical Development, **Cellectis**	**Track Chair:** NADIA HASSOUNAH, Principal Scientist, Translational Immuno-Oncology, **Novartis**	**Track Chair:** MICHAEL GROANING, Global Medical Affairs Lead Genitourinary, **Amgen**

08:55

Fast-Tracking Precision Diagnostics And Tailored Therapeutics For Post-Traumatic Stress Disorder & Traumatic Brain Injury	**Harnessing NK And T Cells Against Cancer Through IL-15 Pathway Activation**	**Preclinical Data Of An Anti-CD3/Anti-ROR1 Bispecific-Armed Oncolytic Virus**	**Biomarkers In The Era Of Immuno-Oncology**
• CVB has built critical infrastructure to support the building of multi-modal mechanistic disease models including resources such as biobanking, analytics pipelines, data sharing platform, and an assay evaluation paradigm • A case-study will be presented with results and takeaway lessons	• Understanding preclinical and clinical MOA • Discussing early clinical results of NKTR-255	• Sorrento's modified oncolytic viruses (OV) platform expressing an αCD3/αROR1 tandem scFv bispecific (bsAb) • αCD3/αROR1 specifically binds to ROR1-expressing tumor cells and CD3+ T cells triggering strong T cell activation • αCD3/αROR1 BsAb showed strong and specific tumor killing activity	• Exploratory RNA expression signature analysis • Pan-tumor TMB analysis for Pembrolizumab • Monotherapies Exploring Cancer Genetic Events and Pembrolizumab Efficacy • Combination Therapies and Exploratory Biomarkers • Emerging Technologies: ctDNA
NICOLE BJORKLUND, Director, Translational Research & Development, **Cohen Veterans Bioscience**	CHRISTIE FANTON, Vice President, Translational Medicine, **Nektar Therapeutics**	YOUG THAKER, Principal Scientist, **Sorrento Therapeutics**	E.J. DETTMAN, Principal Scientist, Clinical Research, **Merck**

09:20

Solution Provider Presentation	**Enabling Biomarker-Driven Clinical Trials**	**State Of The Nation In Cell & Gene Therapy: Navigating The Journeys Within The Journey**	**Spatial Characterization Of The Tumor Microenvironments Using Multiplexed Ion Beam Imaging (MIBI)**
	• Collaborative models for biomarker research • Overcoming barriers to implementing biomarker strategies • Facilitating transition of biomarkers from discovery to development	• Current cell and gene therapy program development and manufacturing scenarios • Program bottlenecks which can derail timelines and how to mitigate them • Considerations of an end-to-end integrated CGT portfolio versus a more fragmented approach • Glimpse into how the field continues to evolve for regulatory, manufacturing, analytics (QA/QC)	• How MIBI technology has enabled deep spatial immunophenotyping of diseased tissue sections • How spatial organization of innate and adaptive immune cell subsets, tumor cells, and structural tissue features were identified with MIBI • How MIBI revealed systems level differences in progressive disease versus treatment-responsive patient groups
Senior Representative, **Volition**	PATRICK HURBAN, Vice President – Translational Genomics & General Manager, Translational Science & Innovation Laboratory, **Nexelis, a Q2 Solutions Company**	KAREN DOUCETTE, Cell and Gene Therapy Navigator, **Charles River**	SAM KIMMEY, Field Applications Scientist, **Ionpath**

09:50 — **Morning Break & 1-2-1 Meetings x4**

	ROOM 1: BIOMARKERS FOR PRECISION MEDICINE & DIAGNOSTIC DEVELOPMENT	ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT	ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: CELL THERAPIES & ANTIBODY THERAPIES	ROOM 4: BIOMARKERS & PRECISION MEDICINE IN IMMUNO-ONCOLOGY
11:10	**Seven Habits Of Highly Effective Biomarkers** • Next generation biomarkers: from omics to precision medicine • Integration of bioinformatics and database-driven approaches • Importance of machine learning in biomarker discovery cycle VOLODIMIR OLEXIOUK, Team Lead AI and Analytics, **BioLizard**	**Precision Medicine In Practice For NSCLC** • Over the past decade, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) has become reliant on tissue specimens and biomarkers to help guide targeted treatment options • By testing a tumor sample for biomarkers, investigators can learn if a cancer has one of these defects, which may point to a specific treatment choice • There are now many biomarker-defined patient subgroups, with evidence showing that treatment with targeted therapies has superior clinical outcomes when compared with cytotoxic agents. However, rapid change in the field of precision medicine brings with it the challenge of translating biomarker recommendations into clinical practice and clinical development • Herein, we will discuss the application of practice guidelines to patients with NSCLC. We will also review novel diagnostic assays, such as Next Generation Sequencing (NGS) and simplex / multiplex immunohistochemistry (IHC) in lung tissue specimens within Cerba Research offerings RANIA GASPO, Global Therapy Area Expert / Oncology, **Cerba Research**	**The Building Blocks Of Antibody Registration And Data Management In CDD Vault** • CDD provides a modern approach to drug discovery research informatics trusted globally by thousands of leading researchers • The CDD Vault is a hosted biological and chemical database management system that helps project teams securely manage, analyze, and present data for biotech companies, CROs, academic labs, research hospitals, agrochemical and consumer goods companies • CDD Vault a is a flexible, configurable system used to register all different types of entities; examples of registered antibodies will be shown JANICE DARLINGTON, Customer Engagement Scientist, **Collaborative Drug Discovery**	**Receptor Occupancy Assays To Improve Dose Selection And Pharmacologic Monitoring** • Immunotherapy employs the use of antibodies that target receptors on immune cell subsets and alter their functions • Assays that assess the binding (receptor occupancy) and the biologic effect of a therapeutic are necessary as part of the drug development continuum • Prior to receptor occupancy (RO) assay development, it is critical to understand the therapeutic mechanism of action (MoA) and reagent availability to ensure a well-defined, reproducible assay • Optimization and validation of a RO assay will greatly improve dose selection and drug effectiveness in clinical trial settings LISA JENNINGS, Managing Executive US, Chief Scientific Officer, Trial Facility Manager, **MLM Medical Labs**
11:40	**Precision Medicine Strategies In Clinical Trials – The Importance Of Diversity In Biomarker Research** *(Joining Online)* ALEKHYA POCHIRAJU, Product Development, Global Operations Manager, **Genentech**	**Translational Biomarkers To Guide Clinical Development For Allogeneic CAR T Cell Therapies** • Translational clinical assays are designed to inform the product characteristics, patient factors, dose, safety, and target strategies for a given allogeneic CAR T-cell therapy • Harmonization of assays and integrated data sets are part of a multipronged approach to translational development that is critical to the success of our current and future therapies KATIE NEWHALL, Vice President of Translational Clinical Development, **Cellectis**	**Advances In Neoantigen Characterization For The Development Of Neoantigen-Specific Therapies** • Improving neoantigen selection for neoantigen-targeted therapy • Characterizing neoantigen-specific T cell responses leading to tumor rejection in preclinical models • Determining new strategy to improve anti-tumor efficacy AUDE-HELENE CAPIETTO, Senior Principal Scientific Researcher, Cancer Immunology, **Genentech**	**Circulating Tumor DNA May Be A Better Surrogate Of Overall Survival Than RECIST Response In Uveal Melanoma Patients Treated With Tebentafusp** *(Joining Online)* KOUSTUBH RANADE, Head of Translational Medicine, **Immunocore**
12:05	**Panel Discussion: Biomarkers For Clinical Development & Precision Medicine** • Developing future precision medicine strategies • Precision medicine tools to transform patient care • Challenges of integrating precision medicine in clinical development **Moderator:** MIKE DAMORE, Director, Translational Oncology Lead, **Pfizer** **Panellists:** GREGORY FRANK, Director, Business Development, **ImaginAb** KENNETH RAMOS, Executive Director, **Texas A&M Institute of Biosciences and Technology** LILING WARREN, Senior Director, Head of Translational Statistics, **Teva Pharmaceuticals**	**Candidate Biomarkers For Pancreatic Cancer - Experience From Clinical Studies** • CTGF as prognostic biomarker in PDAC • Ca 19.9 as candidate predictive biomarker in LAPC • FDG-PET as candidate predictive biomarker in LAPC EWA CARRIER, Vice President, Clinical Development, **Fibrogen**	**Preclinical Development Of A Bispecific Antibody For Neuroblastoma With Improved Efficacy And Reduced Pain** • A standard of care antibody treatment for neuroblastoma causes dose limiting pain due to expression of the target on peripheral nerves • Invenra has used their bispecific antibody platform to more specifically target the neuroblastoma cells and avoid binding to peripheral neurons BONNIE HAMMER, Senior Vice President, Research & Development, **Invenra, Inc.**	**ctDNA Quantitation As A Superior Biomarker Of Efficacy For Immunotherapy In Cancer Compared To Radiology/RECIST** • Cancer immunotherapy drives T cell infiltration into tumors • Measuring lesion size on CT scan is of uncertain value given that lesion size is a balance of tumor cell destruction and T cell proliferation • Longitudinal quantitation of ctDNA may provide superior information versus RECIST ANDREW ALLEN, Co-Founder, President and Chief Executive Officer, **Gritstone bio**

	ROOM 1: BIOMARKERS IN DRUG DISCOVERY & TRANSLATIONAL SCIENCE	**ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT**	**ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: CELL THERAPIES & ANTIBODY THERAPIES**	**ROOM 4: BIOMARKERS & PRECISION MEDICINE IN IMMUNO-ONCOLOGY**
12:30	**Biocartis Partnering - Together Advancing The Future Of Personalized Medicine** Senior Representative, **Biocartis**	**Autoantibody Biomarkers: A Precision Medicine Approach, For The Discovery Of Pathogenic Targets, Tailoring Of Patient Sub-Populations, And The Prediction Of Both Response & Immune Related Adverse Events, For CDx Development** • Early-stage disease detection is possible before symptoms appear • The humoral immune system can be harnessed to identify and read out specific changes initiated by the disease process • By using a novel technology platform and advanced bioinformatics, the resulting biomarker signatures can be used for early diagnosis, intra-disease stratification and the ability to identify appropriate trial populations and therapeutic response expectations ANDREW JACKSON, Director, **Sengenics**	**Using Biomarkers To Guide Precision Medicine: A Global Clinical Trials Laboratory Perspective** ALAN WOOKEY, Vice President, Global Head of Companion Diagnostics (CDx) and Oncology Scientific Advisor, **Nexelis, a Q2 Solutions Company**	**Spatially Resolved Single Cell Analysis Of Lymphoma** • Single cell spatial analysis reveals markers of therapeutic resistance in diffuse large B cell lymphoma • Molecular sub-types of lymphoma are associated with changes in tumor architecture • Comparisons between immune checkpoint responsive and resistant lymphoma identify biomarkers associated with treatment response AKIL MERCHANT, Director, Imaging Mass Cytometry Shared Resource, Associate Professor, Medicine, **Samuel Oschin Cancer Center, Cedars-Sinai**
13:00	**Lunch Break & 1-2-1 Meetings x3**			
14:10	*Delegates are invited to attend the co-located sessions*	**Accelerating Biomarker Discovery & Drug Pipelines With High-Throughput Mass Spectrometry Profiling** • The value of circulating biomarkers to map the non-genetic landscape of human health and disease • How integration of next-gen bioanalytical technologies with computational learning and large-scale human biology databases enables robust biomarker discovery • Case studies in which these technologies have been applied to identify specific biomarkers of biological processes, disease progression, and drug response MO JAIN, Founder and Chief Executive Officer, **Sapient**	*Delegates are invited to attend the co-located sessions*	**Utilizing mIF And Proteomics Analysis To Advance IO Translational Insights** • Simultaneous interrogation of immune infiltrate and spatial proteomic profiling within human tumors • Co-expression with sub-cellular resolution in the characterization of biomarkers targeted by novel agents • Characterizing biological effects of IO therapy on the TME via immunophenotypic profiling ANNA JUNCKER-JENSEN, Principal Scientist, Director Scientific Affairs, **NeoGenomics**
14:40	**Translational PET Imaging Biomarkers In Oncology Drug Discovery And Development** • Overview of Technologies for Non-invasive Preclinical Imaging • Imaging in Evaluating Three Pillars Pharmacology • Application of Classical, Clinically Proven PET Biomarkers in Evaluating Pharmacodynamic Effects ANAND GIDDABASAPPA, Head of Global Science and Technology, Comparative Medicine, **Pfizer**	**Exploratory Prognostic Biomarkers Of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) In Adults With Atypical Hemolytic Uremic Syndrome (aHUS): Analysis Of A Phase 3 Study Of Ravulizumab** • Unmet need for validated prognostic/monitoring biomarkers in CM-TMA • Complement factor Ba and sC5b-9 demonstrate clinical utility in CM-TMA/aHUS • Vascular soluble biomarkers TNF-RI and thrombomodulin, together with factor Ba have prognostic utility TOBIN CAMMETT, Director - Biomarker Development, **Alexion Pharmaceuticals, Inc**	**Phase Ib Study Of An ADCC-Enhanced BAFFR Antibody With Ibrutinib In CLL** • VAY736 is a human monoclonal antibody that depletes BAFF-R+ B cells through ADCC and blocking BAFF signalling • VAY736 is currently in a Ph1 clinical trial with ibrutinib in CLL patients • Our data provide evidence of the potential to safely discontinue ibrutinib through VAY736 add-on therapy NADIA HASSOUNAH, Principal Scientist, Translational Immuno-Oncology, **Novartis**	**Panel Discussion:** ctDNA For Checkpoints And Targeted Therapies • Checkpoints and Targeted Therapies • Regulatory feedback for surrogate end point **Moderator:** ANDREW ALLEN, Co-Founder, President and Chief Executive Officer, **Gritstone bio** **Panellists:** JOHN ROSSI, Vice President, Head of Translational Medicine, **Syncopation Life Sciences** E.J. DETTMAN, Principal Scientist, Clinical Research, **Merck**

	ROOM 1: BIOMARKERS IN DRUG DISCOVERY & TRANSLATIONAL SCIENCE	ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT	ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: CELL THERAPIES & ANTIBODY THERAPIES	ROOM 4: BIOMARKERS & PRECISION MEDICINE IN IMMUNO-ONCOLOGY
15:05	**Translating PD Biomarkers Into Clinical Research** • Complex flow cytometry panels generate a large volume of pharmacodynamic (PD) data that is labor intensive and subjective, necessitating a streamline approach • An automated bioinformatic approach streamlines PD biomarker evaluation for a candidate therapeutic in a preclinical setting MICHELLE GRAHAM, Principal Research Scientist, **AbbVie**	**Validation Of Flow Cytometry In Clinical Trials** VILMA DECMAN, Senior Director, Head of the Cellular Biomarkers, **GSK**	**Panel Discussion:** T Cell Engagers for Bispecifics • The available approaches • Getting additional functional responses from Bispecific vs Monoclonal **Moderator:** BONNIE HAMMER, Senior Vice President, Research & Development, **Invenra, Inc.** **Panellists:** RAJIKA PERERA, Chief Executive Officer, **Poseidon LLC** ALAN WOOKEY, Vice President, Global Head of Companion Diagnostics (CDx) and Oncology Scientific Advisor, **Nexelis, a Q2 Solutions Company**	**Spatial Biology And The Brain Tumour Metastasis Micro-environment** DAVE HOON, Professor, Director, **St. John's Cancer Institute**
15:30	**Advancing Precision Medicine With Multi-Omics** • Precision medicine, offers unprecedented opportunities to improve the effectiveness and efficiency of how drugs are discovered, developed and marketed • Critical to this transformation is the adoption of new technologies and innovative concepts • Multi-omic profiling is advancing these opportunities with increasing momentum to the benefit of patients • How Molecular You's multi-omic platform can be utilized to detect disease earlier and innovate the drug discovery and development processes • Examples on where and how this can be done and the benefits of incorporating multi-omics for greater human-centric R&D value, productivity and risk management • A case study on how Molecular You detects and mitigates chronic disease early • The groundbreaking work the company is undertaking to demonstrate the contribution of molecular biomarkers for early diagnosis, root-cause disease management and patient stratification of Autism Spectrum Disorder ROBERT FRASER, President and Chief Executive Officer, **Molecular You**	*Delegates are invited to attend the co-located sessions*	*Delegates are invited to attend the co-located sessions*	**Functional Engagement Of The PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive Of Patient Response To Immunotherapy In NSCLC** VERONIQUE CALLJEA, Chief Scientific Officer, **Hawk Biosystems**
16:00	**Afternoon Break & 1-2-1 Meetings x4**			

Biomarkers & Immuno US: In-Person
DAY ONE: 03 OCTOBER 2022 | SAN DIEGO, USA

	ROOM 1: BIOMARKERS IN DRUG DISCOVERY & TRANSLATIONAL SCIENCE	ROOM 2: BIOMARKERS FOR CLINICAL DEVELOPMENT	ROOM 3: IMMUNO-ONCOLOGY DRUG DISCOVERY: CELL THERAPIES & ANTIBODY THERAPIES	ROOM 4: BIOMARKERS & PRECISION MEDICINE IN IMMUNO-ONCOLOGY
17:20	**Enhancing Biomarker Discovery In Neurodegenerative Diseases Using Advances In Mass Spectrometry-Based Proteomics** • Biognosys is a world leader in next generation, unbiased mass spectrometry-based proteomics • Workflows are matrix agnostic and can be used for biomarker discovery in tissues, cells and biofluids including CSF and plasma • Peptide-centric analysis provides insights beyond protein expression • Novel workflows significantly improve protein identification depth and confidence • Age is the primary risk factor for neurodegeneration and cognitive decline • Both CSF and plasma profiling enable robust protein biomarker identification that correlate strongly with age (R2 > 0.87) • Additional biomarkers, including subset panels, can be further exploited to predict cognitive decline • In this way, mass spectrometry-based proteomics can be used to identify novel biomarkers that can be used for age and disease prediction with a view towards early identification and treatment options NIGEL BEATON, Scientific Director, Discovery Proteomics, **Biognosys**	**Dismantling Barriers To Biomarker Testing** • Precision medicine is among the key contributors in progressing cancer survivorship • However, utilization of biomarker testing, critical to enabling precision medicine treatments, is below guideline recommendations • The presentation will discuss these barriers and suggest tangible and sustainable solutions that can be done to overcome them – such as equitable access to biomarker testing, standardized care approaches, and biomarker testing education among providers and patients *(Joining Online)* OMAR PEREZ, Head of Medical Diagnostics, US Medical Affairs, Oncology, **AstraZeneca**	**New Avenues For Treating Cancer: TCR-LA Targeting Intracellular Tumor Antigens** • TCR-LA combine the TCR-recognition mode with therapeutic efficacy of conventional mAbs • TCR-LA are mAbs that recognize and bind to peptide/HLA complexes on the tumor cell surface • Immunitrack has a high throughput platform for epitope discovery by conducting affinity and stability assessments of MHC/epitope complexes (NeoScreen platform). With this technology we have identified immunogenic targets of cancer testis antigens and of cancer driver mutations • Immunitrack has implemented and validated a first-in-class TCR-LA characterization platform (AbScreen) STEPHAN THORGRIMSEN, Chief Executive Officer, **Immunitrack**	*Delegates are invited to attend the co-located sessions*
17:50	**Panel Discussion: Harmonising Biomarker Discovery & Validation Efforts** • Harmonising biomarker discovery through academia/pharmaceutical collaboration • Ensuring reproducibility **Moderator:** SIMI AHMED, Senior Vice President, Strategic Partnerships, **NYSCF** **Panellists:** JOHN ROSSI, Vice President, Head of Translational Medicine, **Syncopation Life Sciences** NICOLE BJORKLUND, Director, Translational Sciences, **Cohen Veterans Bioscience** VILMA DECMAN, Senior Director, Head of the Cellular Biomarkers, **GSK**	**Biomarkers Associated With Response And Toxicity To CAR-T Cell Intervention In 2nd Line Large B Cell Lymphoma** • Chimeric Antigen Receptor (CAR) T cell therapy at Kite • Positive outcome of ZUMA-7, the first-ever phase 3 randomized study of Axi-Cel Vs Standard of Care in 2nd line Large B cell Lymphoma • Association of outcome with Pharmacokinetics (PK), Pharmacodynamics (PD), Tumor Biology and Product features SIMONE FILOSTO, Director, Cell Biology, Translational Medicine, **Kite Pharma**	**Developing A Translational Strategy For A T Cell Pipeline** • Understanding the MoA: science-based biomarker strategy • Location vs convenience: tissue vs peripheral biomarkers • Continuous improvement in the search for a breakthrough BYUNG HA LEE, Senior Vice President & Chief Scientific Officer, **NeoImmuneTech**	**Imaging Biomarkers In Patient Selection** MICHAEL GROANING, Global Medical Affairs Lead Genitourinary, **Amgen**
18:15	**Passive Monitoring Using Composite Measures** • Passive, composite digital measures offer high potential for early stage disease detection • To be effective for longitudinal analysis, user-friendly (low friction) devices are essential *(Joining Online)* GRAHAM JONES, Head of Research and Innovation, **Novartis**	**Probiotic, Bif195, Alleviates Intestinal Damage Caused By Intake Of NSAIDs: Understand The Mode Of Action Through Biomarker Analysis** • Strategy of biomarker analysis • Possible Bif195 mode of action • Safety and benefits of Bif195 in relation in to of intake NSAIDs *(Joining Online)* ANDERS DAMHOLT, Head of Clinical Development - Human Health, **Chr. Hansen**	*Delegates are invited to attend the co-located sessions*	**Translation And Biomarker Analysis In Clinical Trials: Operational Considerations** • Identify the operational challenges for global registrational studies • Regulatory challenges to consider • Critical challenges with sample tracking CONRAD MESSAM, Senior Director, **Merck**
18:40	**End of Day One & Drinks Reception**			

DAY TWO: 04 OCTOBER 2022

ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES

Track Chair: LILING WARREN, Senior Director, Head of Translational Statistics, **Teva Pharmaceuticals**

ROOM 3: DISCOVERY & DEVELOPMENT: INTRA-TUMORAL IMMUNOTHERAPIES & COMBINATION STRATEGIES

Track Chair: MEHRAN MOGHADDAM, Chief Executive Officer, **OROX Biosciences, Inc.**

09:00

Track Keynote Address: Dual Toll-Like Receptor 2 And 9 Antagonists For The Treatment Of Neurodegenerative Diseases

- Toll-Like Receptors (TLRs) regulate immune responses to molecular patterns and are implicated in neurodegeneration
- Neuropore has discovered novel small molecule dual TLR2/TLR9 inhibitors that improve disease-relevant endpoints in animal models of ALS and Parkinson's disease

DIANA PRICE, Executive Director, Biosciences,
Neuropore Therapeutics, Inc.

Track Keynote Address: Discovery And Development Of Bifunctional Small Molecules With Novel MOA In Oncology

- OROX is dedicated to discovery of drugs for oncology, inflammatory, and fibrotic diseases
- Our platform technology yields bifunctional small-molecules capable of immunomodulation with exceptional efficacy in preclinical models
- OROX is seeking VC investments and strategic alliance

MEHRAN MOGHADDAM, Chief Executive Officer,
OROX Biosciences, Inc.

ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES	ROOM 2: GENOMIC MARKERS FOR PRECISION MEDICINE & CLINICAL RESEARCH	ROOM 3: DISCOVERY & DEVELOPMENT: INTRA-TUMORAL IMMUNOTHERAPIES & COMBINATION STRATEGIES	ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY
Track Chair: LILING WARREN, Senior Director, Head of Translational Statistics, **Teva Pharmaceuticals**	**Track Chair:** KENNETH RAMOS, Executive Director, **Texas A&M Institute of Biosciences and Technology**	**Track Chair:** MEHRAN MOGHADDAM, Chief Executive Officer, **OROX Biosciences, Inc.**	**Track Chair:** JOHN ROSSI, Vice President, Head of Translational Medicine, **Syncopation Life Sciences**

09:25

Room 1: AI-Based Digital Pathology For NASH

- Biomarkers for the development of NASH therapeutics
- Use AI-based digital pathology to interrogate the disease biology of NASH
- Enable AI-based digital pathology as an aiding tool to improve NASH clinical trials

CHIH-LIANG CHIN, Executive Director, Biomarker & Target Sciences,
Merck & Co., Inc.

Room 2: Effect Of Co-Mutations & FLT3-ITD Variant Allele Frequency (VAF) On Response To Quizartinib Or Salvage Chemotherapy (SC) In Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

- The effect of baseline co-mutations in a trial of R/R AML patients with FLT3-ITD mutations treated with quizartinib were evaluated
- Key co-mutations identified were found to potentially impact treatment response and OS with quizartinib, relative to SC

KEN CHANG, Director, Clinical Biomarkers,
Daiichi Sankyo

Room 3: Novel PROTAC Drugs: Unique Membrane Ubiquitin Ligase That Degrades RTK And Membrane Proteins

- Current PROTAC drugs utilize Cereblon, VHL, HDM2, cIAPs, others ubiquitin ligases that degrade a limited set of intracellular proteins. Progenra has discovered a unique membrane ubiquitin ligase that is remarkably efficient in degrading membrane proteins and receptor tyrosine kinases

TAUSEEF BUTT, President and Chief Executive Officer,
LifeSensors Inc

Room 4: Functional Characterization Of Chimeric Engulfment Receptor (CER) T Cells For The Treatment Of Hematologic And Solid Malignancies

- Development of a single autologous engineered T cell product for use across multiple cancer indications
- Novel CER T-cell products leveraging naturally occurring phagocytic receptors represent a new class of cell therapy products targeting "tumor stress ligands"
- Engulfment and enhanced APC-like function of CER-based products are hypothesized to overcome heterogeneous disease through recruitment of endogenous adaptive and innate anti-tumor immune response

JOHN ROSSI, Vice President, Head of Translational Medicine,
Syncopation Life Sciences

09:50

Room 1: Multiplexed Tools To Spatially Address The Immune Composition Of The Tumor Microenvironment

- How a high-throughput, high-plex (up to 12-plex) staining and mIF assay development can more accurately predict treatment response
- How whole-slide image analysis of the tumor microenvironment, can provide insight into specific cancer types
- How advanced AI-driven image analysis can be applied to discover cell types, populations and morphological context
- Application case studies

BONNIE PHILLIPS, Global FAS Manager,
Ultivue

Room 2: Solution Provider Presentation

Senior Representative,
Personalis

Room 3:

Delegates are invited to attend the co-located sessions

Room 4: Bioassays To Support Development And Characterization Of New Drugs In Immuno-Oncology

- Much of that revolution in immuno-oncology has been fueled by the clinical success of immune checkpoint inhibitors, targeting cytokines, antibody dependent cell cytotoxicity and complement dependent cytotoxicity via the T cell activation
- Reaction biology has established state-of-art high throughput screening procedures for measuring the ability of new Biologics or compounds to activate T cells
- All of our screening procedures and experimental methods will help to identify new therapeutic biologics or compounds for drug discovery in immune-oncology field

MOHAMMAD HAQUE, Senior scientist II,
Reaction Biology

	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES	ROOM 2: GENOMIC MARKERS FOR PRECISION MEDICINE & CLINICAL RESEARCH	ROOM 3: DISCOVERY & DEVELOPMENT: INTRA-TUMORAL IMMUNOTHERAPIES & COMBINATION STRATEGIES	ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY
10:20	**If You Knew Better, You Would Do Better: Identify Superior Biomarkers By Detecting 7000 Proteins At A Time** • Discover what makes proteins potentially ideal for diagnostic, predictive, efficacy, and safety biomarkers across therapeutic areas • When the biomarkers you're looking for are needles in a protein haystack, how can sensitivity, specificity, throughput, and sheer volume of proteins be maximized to optimize your search? • Get an insider's look at the next generation of proteomics; the information it can provide today can deliver the insights, outcomes, and healthcare of tomorrow CLARE PATERSON, Associate Director of Clinical Research, **SomaLogic Inc**	**Translational Research To Revolutionize Dermatologic Care** • Integration and value of non-invasive skin sample collection in clinical trials • Ability of expanded multi-omic analyses to drive biomarker discovery and research • Precision based approaches in clinical trials enable more personalized medicine and improved patient outcomes ERICA MONSANTO, Research Scientist, Stratum, **Dermtech**	*Delegates are invited to attend the co-located sessions*	**Using Chicken Egg In Vivo Assay For High-Value Identification Of Oncology And Immuno-Oncology Drugs Candidates** • How to use INOVOTION's technology to open new perspectives of in vivo screening in oncology and immuno-oncology • Why does the chicken embryo model have several advantages for drug discovery of anti-cancer treatments over traditional in vivo models? • The chicken embryo model fills the gap between in vitro studies and in vivo mouse models, but is it possible to predict mouse data from chicken embryo results? JEAN VIALLET, Chief Executive Officer, **INOVOTION**
10:50	Morning Break & 1-2-1 Meetings x3			
11:50	**Precise Single-Cell, Spatial Phenotyping With ChipCytometry** • How to quantify the expression of dozens of protein biomarkers in in-tact tissue sections with single-cell resolution • How ChipCytometry™ technology can be used to uncover the spatial distribution of immune cell subsets TIM SINDELAR, Product Manager, **Canopy Biosciences**	**A New Frontier In Biomarker Discovery – How The 3D Genome Reveals Novel Disease Mechanisms And Therapeutic Targets Missed By Other Technologies** • Arima Genomics provides 3D genomic technologies that enable scientists to uncover novel disease mechanisms and identify new therapeutic targets. Join us to learn how 3D genomics is enabling biomarker discovery, tumor classification, and patient stratification. In this session, Anthony Schmitt, PhD, SVP of Science at Arima Genomics, will share how 3D genomics is revealing genetic drivers of previously undiagnosed tumors, reshaping how we understand disease, and yielding exciting new opportunities in precision oncology ANTHONY SCHMITT, Senior Vice President, Science, **Arima Genomics**	*Delegates are invited to attend the co-located sessions*	**Mouse Models For Preclinical IO Research And Development** • GemPharmatech's humanization pipeline • New models for Fc gamma receptors and CD3 complexes • Next-generation NCGs SANTI SURYANI CHEN, Associate Director of Immuno-Oncology, **GemPharmatech**
12:20	**Deploying Digital Pathology Scoring In Digital Era** • We present a new metric, pixelwise (pix) H-score, for digitally scoring IHC images for biomarker expression • Through several examples, we illustrate the benefits of the pix H-score over existing scoring algorithms • We also discuss practical applications of pix H-score SRIPAD RAM, Digital Pathology and Image Analysis Group Lead, **Pfizer**	**Elucidating Solid Tumours Through Proteomic Biomarker Discovery** • The role of proteomics in cancer diagnostics • New generation of proteome-based companion diagnostics • Introduction of the Pathology Pillar of the Human Proteome Project (HPP/HUPO) MICHAEL ROEHRL, Professor of Pathology, Lab Medicine, Cell & Developmental Biology, **Memorial Sloan Kettering Cancer Center**	**The Promise Of B-cell Epitope Vaccine Immunotherapies: Tackling Challenges In Combinatorial Checkpoint Inhibitor Vaccines** • PD-L1 and CTLA-4 B-cell epitope vaccines • Combination Immunotherapy HER-2 with PD-1, PD-L1 and CTLA-4 vaccines • 4 syngeneic mice models (CT26, CT26/HER-2; MC38, MC38/HER2; D2F2,D2F2/E2; • Additive/synergistic safe anti-tumor activity PRAVIN KAUMAYA, Professor of Medicine and Director Vaccine Development, **The Ohio State University**	**Scalable Manufacture Of CAR-NK Cells From Engineered Pluripotent Stem Cells With 3-D Bioreactor** • A proprietary scalable 3D iPS-NK manufacture platform with defined, serum-free and feeder-free conditions: pure and strong functional iPS-NK with CD8+ effector cell identity for immunotherapy, a truly viable unlimited/renewable source of immune cells with improved potency and simplified manufacture process • Genetically manipulated and engineered with CARs at pluripotent stage: establishment of permanent, stable and clonal iPS-CAR lines for the manufacture of unlimited homogenous CAR-NK cells. Multiple master iPS-CAR cell banks targeting a variety of antigens for cancer, viral infection and autoimmune diseases: inexhaustible cell sources for all patients • Development of next-generation 3D bioreactor platform and logistics: ultimate goal of making CAR-NK products affordable and available for ordinary patients and as easy to handle and use as conventional drugs JOHN LU, Chief Executive Officer, **HebeCell Corporation**

	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES	ROOM 2: GENOMIC MARKERS FOR PRECISION MEDICINE & CLINICAL RESEARCH	ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY
12:45	**Machine Learning In Imaging Biomarker Development** *(Joining Online)* SEAN XIE, Director, Drug Safety Research & Development, **Pfizer**	**Liquid Biopsy Of LINE-1 Analytes For Early Detection Of Lung Disease** • Aberrant activation of the oncogenic retrotransposon, LINE-1, is a hallmark of lung disease • Measurements of LINE-1 can be used as a "liquid biopsy' of lung pathology • The LINE-1 cargo in extracellular vesicles mirrors the levels in the cells of origin and influenced by sex and ethnicity KENNETH RAMOS, Executive Director, **Texas A&M Institute of Biosciences and Technology**	**Targeting The Tumour Microenvironment For More Effective And Efficient Cancer Immunotherapy** *(Joining Online)* KOUSTUBH RANADE, Head of Translational Medicine, **Immunocore**

13:10	**Lunch Break & 1-2-1 Meetings x3**

	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES	ROOM 2	ROOM 4
14:20	**Panel Discussion:** Novel Techniques & The New Age Of Biomarkers • Biomarker identification and qualification • Matching technology to biomarker context of use and requirements • Utility and challenges of multiple biomarkers • Leveraging public data and evaluating biomarkers in additional diseases **Moderator:** KATHERINE CALL, Former Senior Director, **Sanofi** **Panellists:** SARA FERRANDO-MARTINEZ, Principal Scientist; Head of Clinical Sciences, **NeoImmune Tech** *(Joining Online)* AMANDA KLEIN, Executive Director, Transplant Therapeutics Consortium, **Critical Path Institute** MICHELLE GRAHAM, Principal Research Scientist, **AbbVie**	**Clonal Amplification Of Peripheral B And T Cells Is Associated With Clinical Response To Checkpoint Blockade In Chronic Hepatitis B** • Introduction to single cell sequencing and uses in clinical trials • Example of the use of single cell sequencing in a clinical trial with anti-PD1 • Leveraging single cell data from blood and tissue samples JEFFREY WALLIN, Executive Director, Biomarker Sciences, **Gilead Sciences Inc**	**Preclinical/Clinical Development Of A Neo-Epitope Targeted Monoclonal Antibody For Cancer Therapy** • Antibody/target identification • Mechanisms of action (MOA): ADCC and others • Clinical Trial Development based on MOA PHILIP ARLEN, President and Chief Executive Officer, **Precision Biologics, Inc**

	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES		ROOM 4: PRECLINICAL & TRANSLATIONAL IMMUNO-ONCOLOGY
14:45	**Novel Method For The Generation And Analysis Of Microbiome Data** • MVRSION uses high throughput microfluidics to generate amplicons out of 1000's of reactions at once • Analysis uses an initial alignment which yields bacterial species that MAY be present • Computational filtering results in SPECIES-level calls and abundance SETH CROSBY, Director, Research Collaborations, **Washington University**		**Workshop:** Advances In Combination Therapies **Presentation:** Combination Approaches To Solid Tumours • Gold Nanoparticle-Based-Tumor-Targeting Nanomedicines • TNF • Paclitaxel • Immuno-Oncology • Cytokine combinations GIULIO PACIOTTI, Chief Science Officer, **Cytimmune Sciences, Inc.**

15:10	**Afternoon Break**

	ROOM 1		ROOM 4
15:35	**Challenges And Opportunities In Translational Data Analytics** • ML in biomarker 'omics analysis (e.g. to support patient selection) • Deep learning in translational research • Statistical considerations when translating predictive biomarkers from discovery to clinical development LILING WARREN, Senior Director, Head of Translational Statistics, **Teva Pharmaceuticals**		**Workshop (cont'd.):** Advances In Combination Therapies **Panel Discussion:** Approach From Clinic To Approval • Expectations of regulatory perspectives **Moderator:** RUSSELL LAMONTAGNE, President and Chief Executive Officer, **LaMontagne Gallery** **Panellists:** GIULIO PACIOTTI, Chief Science Officer, **Cytimmune Sciences, Inc.** PRAVIN KAUMAYA, Professor of Medicine and Director Vaccine Development, **The Ohio State University**

	ROOM 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES		
16:00	**Flow Cytometry Tools For Advanced Biomarker Analysis** *(Joining Online)* HONG LIN, Head of Clinical Immunology/Flow Cytometry, **Stony Brook University School of Medicine**		

TRACK 1: BIOMARKER ANALYSIS & EMERGING TECHNOLOGIES

16:25

A Patient Perspective On The Importance Of Biomarker Testing In Cancer Diagnosis - Is It Prime Time Yet? Patients Are Impatient Awaiting The Promise Of Precision Medicine

• You don't need a crystal ball to know patients need predictive biomarkers
• Does NGS stand for Not Good, Sorry if there aren't any treatments to match mutations?
• Smash the silos: sharing data saves lives

(Joining Online) KELLY SHANAHAN, Advocate,
Living With Metastatic Breast Cancer

16:50

Closing Networking & End Of Conference

BIOMARKERS & IMMUNO US: IN-PERSON NETWORKING DRINKS

Monday 3rd October, 6:40pm
in the Exhibition Hall

We hope to see you there

OXFORD GLOBAL CONFERENCES

DoubleTree by Hilton San Diego
MISSION VALLEY

7450 Hazard Center Drive, San Diego, California, 92108, USA

Visit Website

DoubleTree by Hilton San Diego - Mission Valley

7450 Hazard Center Drive,

San Diego, California, 92108, USA

Tel: +1-619-297-5466

DoubleTree by Hilton San Diego - Mission Valley puts you in the center of San Diego. Mission Valley hotel is conveniently located next to the trolley stop, which offers easy transportation to a variety of the city's top attractions including Old Town, Little Italy, Petco Park, San Diego Convention Center, Gaslamp Quarter, and San Diego State University. It is easily accessible by rail, trolly, car, and air.

Detailed travel directions can be found at:

www.oxfordglobal.co.uk/immuno-series-us/ plan-your-visit/

Also known as 'America's Finest City', San Diego is home to Balboa Park, the largest urban cultural park in the U.S., that features 15 museums, numerous art galleries, beautiful gardens, the Tony Award-winning The Globe Theaters and the world-famous San Diego Zoo.

BIOMARKERS SERIES ACROSS 2022

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations. Covering Biomarkers, Genomic Markers, Digital Biomarkers, CTCs & Liquid Biopsies, Flow Cytometry & Multiplex Tools and more.

Biomarkers UK: In-Person
03 - 04 May 2022 | London, UK

Biomarkers US: In-Person
03 - 04 October 2022 | San Diego, USA

Biomarkers Analysis Europe: In-Person
01 - 02 November 2022 | Berlin, Germany

Biomarkers for NASH Symposium
07 December 2022 | Online: GMT (UTC+0)

Members of our Biomarkers Series Community have access to all these events. **Please click here** for more information.

Biologics Series
Proteins & Antibodies | Peptides & Oligonucleotides | Antibody Engineering Vaccines

Cell Series
Cell Culture & Bioprocessing | Cell Therapy Analytics | Cell & Gene Therapy Manufacturing Advanced Therapy Development

Discovery Series
Organ Modelling | Drug Discovery Neuroscience Discovery | Discovery Chemistry

Formulation & Delivery Series
Formulation & Drug Delivery Inhalation & Respiratory Drug Delivery RNA Therapeutics & Delivery Pharmaceutical Lyophilisation Blood-Brain Barrier

Immuno Series
Advances in Immuno-Oncology Autoimmunity & Immunology Tumor Microenvironment Preclinical Immuno-Oncology

NextGen Omics Series
Next Gen Sequencing | Single Cell Analysis Genome Editing | Digital PCR | Spatial Biology SIngle Cell Proteomics

NetZero Series
Sustainability in Pharma & Healthcare

PharmaTec Series
Pharmaceutical IT | SmartLabs & Laboratory Informatics Pharmaceutical Mobile Robotics Digital Medicine

Visit **www.oxfordglobal.co.uk/calendar/** to explore our diverse portfolio of events across 2022.

Visit our Biomarkers Portal

Bringing you the latest research in Biomarkers, Genomic Markers, Clinical & Translational Biomarkers & Biomarker Analysis through a range of Interviews, Industry Insights & Expert Opinions

www.oxfordglobal.co.uk/biomarkers/